The real “patent war” isn’t fought in court—it’s fought in the months before a drug goes generic.
When a brand-name drug’s exclusivity starts to fade, the industry doesn’t just ask, “Will the next generic launch?” It asks a more uncomfortable question:…

AI is already “reading” your drug—whether you want it to or not.
In the patent world, we’ve long treated competitive intelligence like a slow-moving sport: track filings, map claims, monitor litigation, and wait for the next press release. But the co…

Most pharma teams don’t lose because they lack data. They lose because they don’t see the right data at the right time.
That’s the uncomfortable truth behind the “intelligence gap” many organizations still carry—an invisible distance between what’s hap…

Two Systems, One Fight: How the “Patent Dance” and Orange Book Linkage Shape the $400B Biologics War
The biologics market is no longer just a science story—it’s a chess match.
And the opening moves are often invisible to everyone except the lawyers, re…

Most pharma teams don’t lose because they can’t innovate. They lose because they can’t see the clock.
Drug launches are increasingly won—or delayed—by what happens after the science is done: patent cliffs, exclusivity expirations, and the quiet cascade…

AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma has treated “influence” like a human problem: key opinion leaders, conference circuits, advisory boards, and the quiet gravity of a respected clinician’s citation trail. But the ce…

Most companies don’t lose money because they can’t innovate. They lose money because they wait too long.
In pharma, the clock starts ticking long before a patent expires. Yet many teams—business development, licensing, competitive intelligence, even fi…

Drug patent strategy is often treated like a spreadsheet exercise—until it isn’t.
The market doesn’t care that your model is “technically correct.” It cares about timing: when exclusivity ends, when generic entry becomes feasible, when regulatory pathw…